| Last: 0.365 | Day Low: 0.33 | Volume: 62500 |  |
| Change: -0.01 | Day High: 0.36 | Date: 1/27/2012 |
Enter Your Email to Sign Up for
iCo Therapeutics Updates
iCo Therapeutics Updates
Welcome to iCo Therapeutics
iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products: iCo-007, in Phase 2 for the treatment of Diabetic Macular Edema (DME), iCo-008 (Bertilimumab), a product with Phase 2 clinical history to be developed for sight-threatening diseases; and an oral Amphotericin B delivery system for life-threatening infectious diseases. Immune Pharmaceuticals licensed systemic rights to iCo-008 in June 2011. iCo trades on the TSX Venture Exchange under the symbol “ICO”.
iCo Therapeutics trades on the TSX-Venture exchange under the symbol "ICO".
